Healthcare stocks barely moved late Friday, but the biotech sector found a pulse, driven by a strong showing from Moderna. The vaccine maker jumped more than 6% after raising its full-year outlook and posting a surprise third-quarter profit, helping lift the iShares Biotechnology ETF by 1.9%.
The broader healthcare group, by contrast, looked calm: the NYSE Healthcare Index and State Street's Health Care Select Sector SPDR ETF were each down about 0.1%. That split performance highlights how company-specific news, rather than sector-wide trends, is moving healthcare stocks right now.
Moderna's surprise profit
Moderna's gains came after the company reported a third-quarter profit that caught analysts off guard, aided by stronger international sales of its COVID-19 vaccine. The company also raised its full-year guidance, signaling confidence in its near-term prospects even as demand for COVID shots has cooled from pandemic peaks.
For everyday investors, Moderna's move is a reminder that even in a mature market like COVID vaccines, companies can still deliver surprises. The stock's jump also shows how a single earnings beat can ripple through an entire sector ETF, given Moderna's weight in biotech indexes.
Natera slides, Hims & Hers gains
Not all biotech names shared in the rally. Natera, a genetic testing company, slid after reporting a wider-than-expected third-quarter loss. The company had earlier boosted its 2026 outlook, but that failed to stop a 16% share slide, as investors focused on the near-term miss. The episode underscores how quickly sentiment can turn when results fall short of Wall Street's expectations.
On the other end, Hims & Hers Health gained after announcing a deal with Eli Lilly to offer access to Zepbound, a popular weight-loss drug. The partnership is part of a broader trend of telehealth companies expanding into the booming weight-loss market, which has become a major growth area for the pharmaceutical industry.
What it means for investors
For investors, the mixed moves in healthcare and biotech highlight the importance of looking beyond broad sector averages. While the healthcare index was flat, individual stocks swung sharply based on earnings and deal news. That's typical during earnings season, when company-specific catalysts often overshadow macroeconomic trends.
The performance also reflects a broader market backdrop where investors are weighing strong jobs data and elevated yields, which have pressured some sectors. Healthcare, often seen as a defensive play, has held up relatively well, but biotech's higher-risk profile means it can be more volatile.
Looking ahead, investors will likely keep an eye on upcoming earnings from other healthcare and biotech companies, as well as any developments in the weight-loss drug market, which has become a key driver of sentiment. Deals like the Hims & Hers-Zepbound arrangement could continue to reshape the competitive landscape.
For those with exposure to biotech ETFs, Moderna's rally is a positive sign, but it also serves as a cautionary tale about concentration risk. A single stock's earnings can move the whole fund, for better or worse.
As always, it's wise to focus on long-term fundamentals rather than short-term price swings. The healthcare sector's defensive characteristics may appeal to risk-averse investors, while biotech offers growth potential but with added volatility.
